Go offline with the Player FM app!
Mapping Cancer's Hidden Risk—A Global Look at Blood Clots
Manage episode 496346362 series 3495680
Did you know that nearly 1 in 10 cancer patients worldwide may develop a potentially deadly blood clot? In this episode, we speak with researcher Jordan Harry, lead author of a landmark systematic review just published in Cancer Epidemiology, that uncovers which solid tumors carry the highest risk of venous thromboembolism (VTE) and where in the world patients are most vulnerable.
Jordan walks us through surprising insights from their analysis of over 120 studies:
🔹 Why gastroesophageal, ovarian, and brain cancers top the list for clot risk
🔹 What the data reveals about sex-based differences
🔹 How global gaps in reporting may be leaving patients behind
🔹 And what a cancer survivor told her that changed how she views her work
This isn’t just another research summary, it’s a conversation about saving lives by recognizing the often-overlooked danger of cancer-associated thrombosis. If you care about improving outcomes in oncology or want to understand the real-world impact of VTE in cancer care, this is a must-listen.
To access the ISTH Common Data Elements mentioned in this episode: https://isth.breakthrough.healthcare/
To access the Thrombosis Canada Cancer-Associated Thrombosis resources for patients: https://thrombosiscanada.ca/cancer
To access the publication: https://www.sciencedirect.com/science/article/abs/pii/S1877782125000232
Ref: Jordan Harry, Regan Bucciol, Deirdre Finnigan, Hussein Hashem, Ahmad Araki, Maha Othman, The incidence of venous thromboembolism by type of solid cancer worldwide: A systematic review, Cancer Epidemiology, Volume 95, 2025, 102764,
ISSN 1877-7821, https://doi.org/10.1016/j.canep.2025.102764.
Support the show
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
46 episodes
Manage episode 496346362 series 3495680
Did you know that nearly 1 in 10 cancer patients worldwide may develop a potentially deadly blood clot? In this episode, we speak with researcher Jordan Harry, lead author of a landmark systematic review just published in Cancer Epidemiology, that uncovers which solid tumors carry the highest risk of venous thromboembolism (VTE) and where in the world patients are most vulnerable.
Jordan walks us through surprising insights from their analysis of over 120 studies:
🔹 Why gastroesophageal, ovarian, and brain cancers top the list for clot risk
🔹 What the data reveals about sex-based differences
🔹 How global gaps in reporting may be leaving patients behind
🔹 And what a cancer survivor told her that changed how she views her work
This isn’t just another research summary, it’s a conversation about saving lives by recognizing the often-overlooked danger of cancer-associated thrombosis. If you care about improving outcomes in oncology or want to understand the real-world impact of VTE in cancer care, this is a must-listen.
To access the ISTH Common Data Elements mentioned in this episode: https://isth.breakthrough.healthcare/
To access the Thrombosis Canada Cancer-Associated Thrombosis resources for patients: https://thrombosiscanada.ca/cancer
To access the publication: https://www.sciencedirect.com/science/article/abs/pii/S1877782125000232
Ref: Jordan Harry, Regan Bucciol, Deirdre Finnigan, Hussein Hashem, Ahmad Araki, Maha Othman, The incidence of venous thromboembolism by type of solid cancer worldwide: A systematic review, Cancer Epidemiology, Volume 95, 2025, 102764,
ISSN 1877-7821, https://doi.org/10.1016/j.canep.2025.102764.
Support the show
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
46 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.